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Background: In 1999, the United Kingdom (UK) was 
the first country to introduce meningococcal group C 
(MenC) conjugate vaccination. This vaccination pro-
gramme has evolved with further understanding, new 
vaccines and changing disease epidemiology. Aim: 
To characterise MenC disease and population pro-
tection against MenC disease in England. Methods: 
Between 1998/99–2015/16, surveillance data from 
England for laboratory-confirmed MenC cases were 
collated; using the screening method, we updated 
vaccine effectiveness (VE) estimates. Typing data and 
genomes were obtained from the Meningitis Research 
Foundation Meningococcus Genome Library and 
PubMLST  Neisseria  database. Phylogenetic network 
analysis of MenC cc11 isolates was undertaken. We 
compared bactericidal antibody assay results using 
anonymised sera from 2014 to similar data from 1996–
1999, 2000–2004 and 2009. Results: MenC cases fell 
from 883 in 1998/99 (1.81/100,000 population) to 42 
cases (0.08/100,000 population) in 2015/16. Lower VE 
over time since vaccination was observed after infant 
immunisation (p  =  0.009) and a single dose at 1–4 
years (p = 0.03). After vaccination at 5–18 years, high 
VE was sustained for ≥ 8 years; 95.0% (95% CI: 76.0– 
99.5%). Only 25% (75/299) children aged 1–14 years 
were seroprotected against MenC disease in 2014. 
Recent case isolates mostly represented two cc11 
strains. Conclusion: High quality surveillance has fur-
thered understanding of MenC vaccines and improved 
schedules, maximising population benefit. The UK 
programme provides high direct and indirect protec-
tion despite low levels of seroprotection in some age 
groups. High-resolution characterisation supports 
ongoing surveillance of distinct MenC cc11 lineages.
Introduction
Neisseria meningitidis  is a major cause of meningitis 
and septicaemia worldwide. Efforts to control 
meningococcal disease have been aimed at the devel-
opment of effective vaccines and subsequent imple-
mentation in appropriate immunisation schedules. 
Twelve different meningococcal serogroups are recog-
nised and serogroup B (MenB) is currently responsi-
ble for most cases of invasive meningococcal disease 
(IMD) in Europe. Many countries, including the United 
Kingdom (UK), experienced large outbreaks of sero-
group C (MenC) disease in the mid-1990s, due mainly 
to the ST-11 clonal complex (cc11) [1]. In 1999, the UK 
became the first country to introduce the MenC con-
jugate (MCC) vaccine in a phased national campaign 
targeting all those aged less than 18 years over a 
12-month period, alongside a routine three-dose infant 
programme [2]. Vaccine eligibility was later extended 
up to 24 years of age, although this age group was not 
actively called for vaccination. Routine use of MCC vac-
cine in many other European countries followed [3].
As MCC vaccines were licensed on immunogenicity 
studies alone, without direct evidence of clinical effi-
cacy, comprehensive national surveillance was initi-
ated concurrently in order to monitor the vaccines’ 
impact in a population-based setting [2]. MCC vaccina-
tion was associated with rapid and sustained declines 
in MenC disease across all age groups through direct 
and indirect (herd/population) protection [3-5]. 
Invasive disease is rare following nasopharyngeal 
acquisition where the meningococcus can persist for 
several months before it is cleared; this asymptomatic 
carriage, especially in older teenagers, is an impor-
tant reservoir for infection, onward transmission to 
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susceptible individuals and immunity. In the UK, there 
was a 66% reduction in MenC carriage among 15–19 
year-olds within 1 year of MCC vaccine implementation 
and this reduction was key to establishing indirect pro-
tection across the population [6].
The UK MCC immunisation programme has evolved over 
time (Box) and, from 2013, has included an adolescent 
MCC vaccine programme to extend direct protection 
in teenagers and maintain indirect protection in the 
wider population. In 2015, this vaccine was replaced 
with the quadrivalent meningococcal conjugate vac-
cine (MenACWY) to combat a national MenW outbreak. 
A multi-component, protein-based vaccine against 
MenB was also implemented in the infant immunisa-
tion schedule at the same time [7]. In July 2016, the 
infant MCC dose was removed because MenC cases 
were extremely rare in this age group and population 
protection was likely to be maintained through the 
adolescent MenACWY programme.
Methods
National epidemiology
Public Health England (PHE) conducts enhanced 
national surveillance of IMD in England. The PHE 
Meningococcal Reference Unit (MRU) provides a 
national service for confirming, grouping and charac-
terising invasive meningococcal isolates [11]. The MRU 
also provides free national Polymerase Chain Reaction 
(PCR)-testing of clinical samples from patients with 
suspected IMD; Diagnostic laboratories are required by 
law to notify PHE when they identify  Neisseria menin-
gitidis and samples are requested to be sent to the MRU 
for confirmation and characterisation. PHE routinely 
reconciles laboratory-confirmed cases to generate 
a national dataset [12] and follows up each case for 
demographic data, vaccination history, clinical presen-
tation and outcomes through Health Protection Teams 
(HPTs), general practitioners and, for younger cases, 
hospital clinicians. Details documented on HPZone (a 
web-based software for public health management of 
infectious diseases used by HPTs throughout England), 
were also accessed by PHE to obtain additional infor-
mation on cases since 2010.
Vaccine effectiveness
Using the national dataset, MCC VE was calculated 
using the screening method [13] for confirmed MenC 
cases among MCC-eligible individuals (born since 1 
September 1981) in England between 01 January 2000 
and 30 June 2016. VE was estimated according to time 
since vaccination (or, if unvaccinated, since the age 
at last scheduled dose); analysis included unvacci-
nated children, those who had completed the recom-
mended primary immunisation course for their birth 
cohort (three doses for those aged 1 year of less before 
September 2006), or had received one dose after 
their first birthday at any age. Effectiveness of the 
primary plus booster dose was based on cases who 
had received ≥  1 primary MCC dose followed by the 
12-month Hib/MCC booster. The following formula was 
used:
VE = 1 − [PCV(1 − PPV)]/[(1 − PCV)PPV]
Where PCV is the proportion of vaccinated MenC cases 
and PPV is the proportion of vaccinated population 
(i.e. vaccine coverage, matched to each case based on 
their age and birth cohort and then averaged). Annual 
national vaccine coverage by 12 months of age (from 
April 2001) and by 24 months of age (from April 2002) 
was used for the latter [14].
Data extracted in May 2016 from The Health 
Improvement Network (THIN) database [15] for children 
born from August 1999 to May 2015 was used to esti-
mate partial vaccination proportions for each of the 
routine schedules (3  +  0, 2  +  1, 1  +  1) by 12 months 
Box  
Summary of the changing United Kingdom 
meningococcal immunisation schedule, 1999–2016 
1999: Routine infant vaccination at 2, 3 and 4 months of 
age MenC vaccine
- Catch-up of children aged 5 months to 18 years MenC 
vaccine
2006: Routine infant vaccination at 3 and 4 months of age 
MenC vaccine
- Booster (of MenC) at 12 months of age MenC/Hib vaccine
2013: Routine infant vaccination at 3 months of age MenC 
vaccine
- Booster (of MenC) at 12 months of age MenC/Hib vaccine
- Booster at 13–15 years of age MenC vaccine
2015: Routine infant immunisation at 2 and 4 months of 
age MenB vaccine
- Routine infant immunisation at 3 months of age MenC 
vaccine
- Booster at 12 months of age MenB vaccine
- Booster (of MenC) at 12 months of age MenC/Hib vaccine
- Routine teenage dose at 13–15 years of age MenACWY 
vaccine
- Catch-up of teenagers aged 15–18 years MenACWY 
vaccinea
2016: Routine infant immunisation at 2 and 4 months of 
age MenB vaccine
- Booster at 12 months of age MenB vaccine
- Primary dose (of MenC) at 12 months of age MenC/Hib 
vaccine
- Routine teenage dose at 13–15 years of age MenACWY 
vaccine
a Completed in 2017.
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and 24 months of age. These estimates of partial vac-
cination were used to adjust the national coverage esti-
mates to give coverage in those who received either no 
vaccination or the full the schedule. For example, it was 
estimated that in the three-dose primary cohort, 5.5% 
received one or two doses by 12 months, so national 
coverage of 90% for three doses would be adjusted to 
(90*100)/(100–5.5)  =  95.2%, once partial vaccination 
is excluded.
Molecular characterisation
Typing data and genomes were obtained from the 
PubMLST Neisseria database and Meningitis Research 
Foundation (MRF) Meningococcus Genome Library 
(MGL), to which all MRU isolates from the national data-
set have been referred since July 2010 [16,17]. A recent 
phylogenetic network analysis of the known popula-
tion structure of MenC-associated cc11 sublineages 
was re-annotated in the context of the current study 
since cc11 represented the majority of recent invasive 
MenC isolates in England [18]. Briefly, all available 
global cc11 genomes, including 121/122 invasive MenC 
isolates from England (2010/11–2015/16), and exclud-
ing serogroup W-associated lineage 11.1 sublineages 
(final n = 898 globally; accessed 7 October 16), and two 
non-cc11 reference genomes (IDs 27778 and 29645; 
ccs 41/44 and 8, respectively), underwent core genome 
comparisons (1546 loci) using the PubMLST genome 
comparator tool. The resulting distance matrices were 
visualised using SplitsTree4. The invasive MenC cc11 
isolates collected in England during 2010/11–2015/16 
(inclusive) were highlighted [19].
Serosurvey
Serum samples collected in 2014 were obtained 
from the PHE Seroepidemiology Unit; a depository 
of anonymised residual sera from routine diagnostic 
testing at participating laboratories. Known immuno-
compromised individuals are excluded from the collec-
tion. The age, sex and year of collection were known 
for individual samples: immunisation status was not 
known [20].
Serum bactericidal antibody (SBA) assays were per-
formed against the serogroup C target strain, C11 (phe-
notype C:16: P1.7–1,1) as previously described [21]. The 
complement source used in the SBA was pooled serum 
from 3–4 week old rabbits (Pel Freez Biologicals, 
Arkansas, United States (US)). Titres were expressed 
as the reciprocal serum dilutions yielding ≥  50% kill-
ing after 60 minutes. The lower limit of detection was a 
titre of 4. Titres of < 4 were assigned a value of two for 
geometric mean titre (GMT) analysis. Titres of ≥ 8 were 
considered protective against MenC disease [22].
Approximately 100 samples were selected from each 
age-band to fit with different vaccine schedules since 
MCC introduction and to allow comparison with previ-
ous studies. This sample size was selected to achieve 
reasonable precision around the 95% confidence inter-
vals (CIs) for proportions with SBA titres ≥ 8 and GMTs 
within the age group of interest.
Since MCC vaccine coverage has been consistently 
high, the age of the serum donor was used to align the 
donor with the MenC vaccine schedule they should have 
been offered and thereby identify which MenC vaccine 
cohort they belonged to. This then allowed compari-
son of protection between schedules and over time, 
using historical data from three previously published 
similarly designed surveys. These earlier surveys used 
sera collected from the same Seroepidemiology Unit 
and tested using the same methodology in the same 
PHE laboratory during 1996–1999 [8], 2000–2004 [9] 
and 2009 [10].
Table 1
Total number of confirmed group C meningococcal disease cases, England, 2006/17–2015/16 (N = 268)
Epidemiological year
Age group (years)
< 1 1–4 5–9 10–14 15–19 20–24 25–44 45–64 ≥ 65 Total
2006/07 2 2 2 0 1 3 7 7 4 28
2007/08 1 2 1 0 4 2 7 4 7 28
2008/09 0 1 1 2 0 0 1 7 1 13
2009/10 1 4 3 1 1 0 5 2 0 17
2010/11 2 3 2 1 1 0 6 4 3 22
2011/12 3 3 2 1 3 2 8 4 3 29
2012/13 0 1 1 4 3 3 9 7 5 33
2013/14 1 2 5 2 0 1 7 6 3 27
2014/15 1 0 6 0 3 0 10 7 2 29
2015/16 1 1 4 3 3 1 13 7 9 42
Total 12 19 27 14 19 12 73 55 37 268
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Results
Epidemiology
MenC cases in England fell rapidly from 883 in 1998/99 
(pre-vaccination year, incidence 1.81/100,000) to 13 
cases in 2008/09, continuing at low levels (17–33 
cases annually) during 2009/10–2014/15. In 2015/16, 
there were 42 cases (0.08/100,000), similar to dis-
ease levels last observed in 2004/05 (Table 1,  Figure 
1). Over the last decade, the age distribution has been 
relatively constant (Figure 1). However, the proportion 
of cases among those aged 5–14 years increased from 
12% between 2006/07–2010/11 (0.04/100,000) to 
17% between 2011/12–2015/16 (0.09/100,000), while 
the proportion of cases among 1–4 year-olds declined 
from 11% (0.09/100,000) to 4% (0.05/100,000) over 
the same period. Cases in those aged 45 years and 
over (who were not vaccine eligible) were 86% lower in 
2015/16 (n = 16) than 1998/99 (n = 111) consistent with a 
sustained population protection effect.
Between 2011/12 and 2015/16, 160 MenC cases were 
confirmed and 18 died (case fatality rate (CFR), 11%). 
The London region, where 16% of the English popula-
tion resides (8.7 of 54.8 million) accounted for 41% of 
cases (n  =  66). Overall, 82 cases were female and 78 
male but the sex distribution differed by age with a pre-
ponderance of males aged 25–44 years (30/47, 64%) 
and of older female cases aged ≥ 45 years (35/53,66%). 
Thirty-two cases (20%) had a history of recent travel, 
17 cases were born outside the UK and were more likely 
to have recently travelled (15/17, 88%) than individuals 
born in the UK (17/143, 12%).
Of the 160 cases, 11 (7%) were living in shared accom-
modation (three university students, four in care 
homes or assisted living, four in house share or hostel 
accommodation). There were six cases in known men 
who have sex with men (MSM) and eight individuals 
reported using recreational drugs, were injecting drug 
users or had alcohol dependency. Nineteen cases (12%) 
had underlying co-morbidities; heart condition (n = 3), 
diabetes (n = 2), HIV (n = 6), immunosuppression (two 
on psoriasis treatment, one with chronic lymphocytic 
leukaemia, one post liver transplant), chronic respira-
tory condition (n = 3), liver disease (n = 3). There were 
three clusters of two cases each in primary schools 
nationally in 2015; all six children were fully-vaccinated 
(two-dose primary course with booster).
Vaccine effectiveness
Between 1 January 2000 and 30 June 2016, there 
were 316 MenC cases in vaccine-eligible individuals, 
of whom 119 had been fully-vaccinated according to 
their recommended schedule (Table 2). Estimated VE 
within 12 months of immunisation at all targeted ages 
(including infants) was high at 91% to 96%. Following 
routine infant vaccination or a single dose adminis-
tered to cohorts aged 1 to 4 years when the catch-up 
programme began, a trend for lower VE with increasing 
time since vaccination was observed (p  =  0.009 and 
p = 0.03 respectively) (Table 2). In school-aged cohorts 
(aged 5–18 years when immunised), high VE was sus-
tained over time, remaining at 95.0% (95% CI: 76.0 
to 99.5%) at least 8 years after vaccination. Of the 26 
cases eligible for the Hib/MenC booster, 25 were vac-
cinated, with matched coverage of 94.6%; VE was -43% 
but with wide confidence intervals (95% CI: -5,759 to 
77). This calculation is very sensitive to the number of 
unvaccinated cases; for example, the addition of just 
two unvaccinated cases would change this estimate to 
52%.
Molecular characterisation
During 2010/11–2015/16, there were 182 laboratory-
confirmed MenC cases in England’s national dataset, 
of which 122 were culture-confirmed. Molecular char-
acterisation was available for 121 isolates, 89 of which 
(73.6%) belonged to the ST-11 clonal complex (cc11); 
ranging from 4 of 12 in 2010/11 to 27 of 30 in 2015/16. 
Other clonal complexes included cc103 (n  =  9), cc269 
(n  =  6), cc-unassigned (n  =  5), cc32 (n = 3), cc41/44 
(n = 3), cc174 (n = 2) and a single isolate each for cc116, 
cc23, cc334 and cc60 (Figure 2). The population struc-
ture of cc11 (minus the MenW-associated lineage 11.1 
sublineages) [18] comprised two main lineages, line-
age 11.1 (corresponding to ET-37; n = 245; 6 MenB, 229 
MenC, 1 MenY and 9 serogroup unspecified) and lin-
eage 11.2 (corresponding to ET-15; n  =  649; 77 MenB, 
536 MenC, 3 MenW and 33 non-groupable/serogroup 
unspecified) (Figure 3a).
The English cc11 case isolates from 2010/11 to 2015/16 
belonged to both lineage 11.1 (n  =  32; 36.0%) and 
Figure 1
Incidence rate of group C meningococcal disease by 
epidemiological year, England, 1998/99–2015/16
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Table 2
Meningococcal serogroup C conjugate vaccine effectiveness based on the screening method in immunised cohorts, England, 
September 2000–June 2016
Cohort
Approx 
age at 
MCC 
vaccine
Average 
matched 
population 
coverage 
 
%
Proportion of cases 
vaccinateda Overall vaccine 
effectiveness % 
(95% CI)
Vaccine effectiveness based on 
time since vaccination % 
 
(95% CI)
Trend 
analysisb
n/N % Within 1 
year More than 1 year
Routine 
infantc,d,e 
 
(0 or 3 doses 
only)
2, 3, 4m 95.9 51/61 83.6 78 (52 to 89) 94 (80 to 98)
Overall 44 (-182 to 82) 
 
12–23m 58 (-1,708 
to 94) 
 
24–35m 64 (-1,495 
to 95) 
 
36 + m 14 (-3,436 to 
86)
P = 0.009
Routine 2 + 1 
schedulef 
 
(0 or 3 doses 
only)
2, 4, 12m 94.6 25/26 96.2 -43 (-5,759 to 77) too few cases NA
Infant catch-up 
(0 or 2 doses 
only)
5–11m 80.2 6/16 37.5 85 (55 to 96) 91 (-8 to 100) 83 (36 to 96) P = 0.58
Toddlers 
catch-up 
 
(0 or 1 dose)
1–2y 80.2 11/27 40.7 83 (61 to 93)%
96 (87 
to 99)
Overall 89 (81 to 94) 
 
12–23m 92 (66 to 99) 
 
24–47m 77 (11 to 95) 
 
48–95m too few cases 
 
96m + 75 (3 to 94)
P = 0.03
Pre-school 
catch-up 
 
(0 or 1 dose)
3–4y 71.9 7/47 14.9 93 (85 to 97)
Infant school 
catch up 
 
(0 or 1 dose)
5–6y 57.7 3/23 13.0 89 (63 to 98)
95 (88 
to 98)
Overall 94 (90 to 96) 
 
12–23m 93 (80 to 98) 
 
24–47m 87 (63 to 96) 
 
48–95m 97 (87 to 100) 
 
96m + 95 (76 to 99)
P = 0.33
Junior school 
catch up 
 
(0 or 1 dose)
7–10y 84.2 3/10 30.0 92 (65 to 99)
Secondary 
school catch-
upg 
 
(0 or 1 dose)
11–16y 85.0 8/55 14.5 97 (94 to 99)
Sixth form 
catch-upd 
 
(0 or 1 dose)
17–18y 60.1 5/51 9.8 93 (82 to 98)
Total All ages NA 119/316 37.7 NA NA NA NA
CI: confidence interval; m: months; MCC: meningococcal serogroup C conjugate; NA: not available; y: years.
a Unvaccinated cases are based on the date of birth cohort each individual belongs to.
b Trend analysis was done by logistic regression for the odds of vaccination in cases against log-time since vaccination with an offset of the 
log-odds of matched coverage. The exception was for the infant catch-up, where time was modelled as within a year and beyond a year as 
numbers were too small to model a trend.
c Using DoH cover with THIN partial vaccination correction.
d Including cases from January 2000.
e Including one vaccinated case scheduled for three infant doses but only given a single dose after 12 months of age.
f Including cases from April 2006.
g Including cases from April 2000.
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lineage 11.2 (n  =  57; 64.0%), where they mainly 
belonged to several closely-related clusters (Figure 3a). 
The predominant PorA subtypes were P1.5,2 (93.8%) 
and P1.5–1,10–8 (96.5%), respectively. Since 2010/11, 
the number of lineage 11.1-related cases increased 
from one to 10 per year, while the lineage 11.2-related 
cases varied between three (2010/11) and 17 (2015/16) 
(Figure 3b,c). Isolates from vaccine-failure cases were 
randomly distributed among the overall English MenC 
cc11 population (not shown).
Serosurvey
Results were available for 993 samples collected in 
2014 and 323 (33%; 95% CI: 30.1 to 35.9) had SBA 
titres ≥  8. The proportion of individuals achieving the 
seroprotective threshold was remarkably similar across 
the age groups in 2014 compared with 2009 (Figure 4). 
In contrast, much higher proportions of 5–19 year-olds 
were seroprotected during 2000–04, the period imme-
diately after the 1999/2000 national catch-up for 0–18 
year-olds. This cohort is now older and responsible for 
the secondary peak of seroprotection among 15–34 
year-olds in subsequent serosurveys. Notably, only 
38% of 15–19 year-olds achieved the seroprotective 
threshold in 2014 compared with 56% in 2009. Only 
25% (75/299) children aged 1–14 years were seropro-
tected against MenC in 2014.
The 14/15 year-olds and 16 year-olds were separated 
in 2014 because they received different primary vacci-
nation (Table 3) and to maintain consistency with the 
2009 survey. Analysis by birth cohort and eligible vac-
cine schedule indicated higher GMT (10.6; 95% CI: 4 to 
29 vs 3.7; 95% CI: 2 to 6) and proportions with SBA 
titres > 8 (28.2%; 95% CI: 15 to 44 vs 17.0%; 95% CI: 8 
to 30) among 14–15 year-olds (the cohort eligible for 
the adolescent booster) in 2014 compared with 2009 
(Table 3). In the younger age groups, GMTs and propor-
tion protected were generally lower in 2014 compared 
with 2009 (Table 3).
Discussion
Epidemiology
MenC disease in England remains at very low lev-
els with an incidence of 0.08/100,000 in 2015/16, an 
overall reduction of 95.6% compared with 1998/99 
before MCC vaccination was introduced. Nearly a third 
of cases are currently diagnosed in 25–44 year-old 
adults, many with clinical, social and travel-related 
risk factors. Overall case fatality remains unacceptably 
high. Updated VE estimates indicate a rapid decline in 
protection after 1 year following routine infant immuni-
sation, but this remains high in children immunised at 
school age (5–18 year-olds) up to at least 8 years after 
vaccination.
The low MenC disease incidence is reassuring and 
is consistent with continued herd protection in the 
wider population and high direct protection in those 
who have been vaccinated. There have been no cases 
reported among at-risk individuals, currently defined 
as those with asplenia, splenic dysfunction or comple-
ment deficiency. Those born outside the UK (who are 
less likely to be immunised with MCC, even if eligible 
on entry), recently travelled and/or socially mixing with 
these populations accounted for a quarter of all cases, 
while a significant proportion of the other cases were 
living in shared or supported accommodation, which 
is a known risk factor for IMD [23]. An increased risk 
of IMD in HIV-positive individuals has recently been 
reported [24], even among those receiving appropriate 
antiretroviral therapy. Over the past 5 years, six HIV-
positive individuals were identified among 160 MenC 
cases in England, all in the 25–44 year age group, 
including two who were non-UK born and had recently 
travelled abroad: Outbreaks of MenC disease in MSM 
populations have been reported in North America 
and Europe [25,26]. Whole genome sequencing previ-
ously showed that MenC case isolates among MSMs in 
England, while all belonging to lineage 11.2, were inter-
spersed among sporadic community case isolates and 
did not form a discrete cluster [27].
Figure 2
Clonal complex distribution among meningococcal 
serogroup C case isolates, England, 2010/11–2015/16
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Figure 3
Diversity and temporal distribution of meningococcal serogroup C case isolates, England, 2010/11–2015/16
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A) Neighbor-net phylogenetic network based on a comparison of 1,546 core genes among all available cc11 genomes on the PubMLST 
database, excluding predominantly-serogroup W lineage 11.1 sublineages (final n = 898; accessed 07/10/16). The English meningococcal 
serogroup C case isolates from 2010/11 to 2015/16 (red dots) were mainly distributed among several closely related lineage 11.1 and lineage 
11.2 clusters, respectively. B) Cases due to lineage 11.1 isolates have increased since 2010/11, whilst C) cases due to lineage 11.2 isolates have 
fluctuated.
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Molecular characterisation
Recent MenC cases in England were caused by diverse 
meningococcal strains, representing at least 10 dif-
ferent clonal complexes over the past 6 years. Most 
cases, however, were caused by two diversifying cc11 
strains, one each from the two recently-resolved major 
cc11 lineages (lineages 11.1 and 11.2) [27,28]. Our 
findings warrant continued close monitoring, as line-
age 11.1 cases have increased steadily over the past 
6 years, while 2015/16 also saw the greatest number 
of lineage 11.2 cases. In addition to high case fatality 
rates for cc11 in general, the presence of lineage 11.2 
isolates is concerning for several reasons. Evidence of 
frequent MenB to MenC capsule switching is coupled 
with poor potential coverage by, and the ability to 
escape from, several existing and experimental MenB 
vaccines [18]. Furthermore, distinct lineage 11.2 popu-
lations have independently acquired traits that may 
facilitate urogenital colonisation [29,30]. The acquisi-
tion of intact  aniA  alleles encoding nitrite reductase 
may enable survival in microanaerobic environments 
and has been associated with outbreaks of invasive 
disease among MSM in the US and Europe [30-32] and 
urethritis among heterosexual males in the US [29,30]. 
The urethritis-associated strain has also lost its abil-
ity to express a capsule, a further gonococcal trait that 
may facilitate adherence to the urogenital mucosa.
Serosurvey
Seroprevalence studies have proven valuable in 
improving our understanding of population immunity, 
inform mathematical modelling and can complement 
disease surveillance to help inform national vaccine 
policy [8-10]. The 2014 serosurvey confirmed the rapid 
decline in immunity after infant and toddler immunisa-
tion (also observed with the 2009 serosurvey) as well 
as the low proportion of teenagers protected against 
MenC disease around the time when the adolescent 
programme was introduced. Similar trends have been 
reported in the Netherlands, where a large catch-up 
campaign targeting 1–19 year-olds in 2002 was fol-
lowed by routine childhood immunisation at 14 months 
of age only. Here, a recent serosurvey found only 19% of 
10 year-olds were protected 9 years after a single MCC 
dose at 14 months [33]. The successful control of MenC 
disease in the UK is attributed to the large catch-up 
campaign in 1999/2000. Teenagers and young adults 
have the highest nasopharyngeal meningococcal car-
riage rates and are considered the main source of 
spread. MCC vaccines not only protect against invasive 
disease but also against nasopharyngeal acquisition, 
thereby inducing herd protection across all age groups 
[4,6]. The current cohort of younger children with poor 
seroprotection is most likely protected against disease 
because of this indirect protection.
Most adolescents in 2014 will have received a three-
dose infant MCC schedule without a booster. The low 
proportion of teenagers achieving protective antibody 
thresholds in the 2014 serosurvey indicated there was 
poor long-term direct protection in the cohort that was 
only immunised in infancy and ongoing herd protec-
tion across the population could be threatened. This 
observation, predicted after the 2009 serosurvey, 
helped support the inclusion of MCC in the adolescent 
programme in 2013 with the aim of providing high anti-
body concentrations throughout the peak years of car-
riage [7]. The 2014 serosurvey is already demonstrating 
higher MCC antibodies among 14–16 year-olds com-
pared with the same age group in the previous serosur-
vey. The emergency adolescent MenACWY programme 
in 2015 was implemented to provide direct and indirect 
protection, not only against MenC but also against 
the three other serogroups; particularly the emergent 
hypervirulent MenW strain also belonging to cc11 that 
was responsible for a quarter of all IMD cases across 
the UK by 2014/15 [7].
Implications for other countries
In Europe, MenC disease incidence is currently low 
(< 1/100,000) in countries with and without routine MCC 
vaccination [3]. Disease in infants remains rare and 
thus in countries with routine MCC immunisation most 
cases occur in adults, with a median age of 41 years 
compared with 22 in countries without MCC vaccina-
tion programmes. The recent increase in MenC cases in 
France highlights the importance of maintaining high 
vaccine coverage, especially in adolescents, in order 
to sustain long-term direct and indirect disease control 
Figure 4
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[34]. A number of countries across Africa, Latin America 
and elsewhere are also experiencing high MenC dis-
ease activity [35,36]. Travellers to such countries, 
including residents visiting family and friends in their 
home countries, should be appropriately immunised, 
advised to avoid high-risk behaviours, remain vigilant 
for symptoms and signs of meningococcal disease 
and seek immediate medical help if concerned while 
abroad and when returning to their home countries.
Strengths and limitations
The strength of this study is the consistently high 
quality of the national surveillance programme with 
high case ascertainment [12] and active follow-up of 
cases since 1998/99. This has allowed us to monitor 
VE in different cohorts over time. Our meningococ-
cal surveillance is complemented with clinical trials, 
to assess the immunogenicity of different schedules, 
and serosurveys to monitor population susceptibility. 
Together, these results have allowed us to adapt the 
national immunisation programme to provide maximal 
long-term protection in the most cost-efficient man-
ner. Using the same methodology allows us to moni-
tor population effects over time. A limitation of the 
serosurvey, however, is that we have no information on 
the vaccination status of the serum donors or their clin-
ical state. Nonetheless, the large numbers of samples 
tested, along with the consistently high vaccine cover-
age nationally has allowed us to analyse the results by 
birth-cohorts.
Conclusions
We found evidence for rapid waning of immunity follow-
ing routine infant immunisation, even with a 12-month 
booster, which was introduced in 2006. Currently, 
most toddlers (1-4 years) and older children (aged 5-13 
years) in England are not seroprotected against MenC 
disease and are dependent on the indirect protection 
offered through reduced carriage in young people aged 
17-24 years. It is, therefore, reassuring that there is 
still evidence of herd protection in adults 17 years after 
mass vaccination of children in 1999. Immunisation of 
teenagers appears to be key for continued population 
impact, but also for direct protection before their social 
behaviour leads to greater exposure, carriage and 
invasive disease. We have demonstrated high short-
term effectiveness of MCC vaccines in infants and pre-
school children and the long-term effectiveness of MCC 
Table 3
Proportion of samples with serum bactericidal antibody titres ≥ 8 and geometric mean titres by birth cohort and vaccination 
schedule
Vaccination schedule for birth 
cohort
Birth 
period
Age in 
2009 
 
(years)
Age in 
2014 
 
(years)
2009 Survey (95% CI)a 2014 Survey (95% CI)
n % ≥ 8 GMT n % ≥ 8 GMT
2006 schedule: 2 + 1 schedule 2006–08 1–3 6–8 133
31.6 
 
(24 to 40)
7 
 
(5 to 10)
68
19.1 
 
(11 to 30)
4.2 
 
(3 to 6)
Three dose infant schedule
2004–05 4–5 9–10 63
30.2 
 
(19 to 43)
5.7 
 
(4 to 9)
37
24.3 
 
(12 to 41)
3.5 
 
(2 to 5)
2001–03 6–8 11–13 76
29.0 
 
(19 to 41)
4.8 
 
(3 to 7)
52
21.2 
 
(11 to 35)
3.5 
 
(2 to 5)
1999–2000 9–10 14–15b 53
17.0 
 
(8 to 30)
3.7 
 
(2 to 6)
39
28.2 
 
(15 to 44)
10.6 
 
(4 to 29)
Catch-up in second year of life 1998 11 16 b 32
15.6 
 
(5 to 33)
3.4 
 
(2 to 6)
14
35.7 
 
(13 to 65)
7.6 
 
(2 to 28)
Toddler/preschool 1995–97 12–14 17–19b 101
31.7 
 
(23 to 42)
7.2 
 
(5 to 11)
54
38.9 
 
(26 to 53)
8 
 
(4 to 15)
Primary school 1990–94 15–19 20–24b 132
56.1 
 
(47 to 65)
27.5 
 
(18 to 
43)
97
61.9 
 
(52 to 72)
20.6 
 
(12 to 35)
Secondary school 1982–89 20–27 25–32 165
55.8 
 
(48 to 63)
28.3 
 
(19 to 
42)
54
44.4 
 
(31 to 58)
15.80 
 
(7 to 33)
CI: confidence interval; GMT: geometric mean titre.
a Data from Ishola et al., 2009.
b These age cohorts would include some individuals targeted for MenC vaccination as part of the adolescent/Fresher MenC vaccination 
introduced in 2013.
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vaccines given to school-aged children and adoles-
cents. These findings have led to several revisions of 
the UK immunisation schedule to maximise direct and 
indirect protection. The recent change to emergency 
MenACWY vaccination for teenagers was brought in to 
provide more rapid population control for the national 
MenW outbreak. It should also provide continued 
direct and population control for MenC and help estab-
lish this for MenY disease.
Continued epidemiological and microbiological surveil-
lance will be critical to monitor current programmes 
which now include newer sub-capsular protein-based 
vaccines against MenB disease in infants. MenC dis-
ease continues to be rare but detailed case-based 
follow-up has identified certain groups that remain 
at higher risk for MenC disease despite containment 
within the wider population, these groups may benefit 
from targeted vaccination. Stochastic meningococcal 
outbreaks globally need to be carefully monitored, 
as well as the recent MenC outbreaks among MSM. 
High-resolution characterisation is critical to moni-
tor circulating strains and detect known and unknown 
emerging threats.
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